<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1365928</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1365928</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Exosomes derived from HUVECs alleviate ischemia-reperfusion induced inflammation in neural cells by upregulating KLF14 expression</article-title>
<alt-title alt-title-type="left-running-head">Qin et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1365928">10.3389/fphar.2024.1365928</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Qin</surname>
<given-names>Jianxin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhou</surname>
<given-names>Lihong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yu</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ye</surname>
<given-names>Jingwen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Feng</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Jin</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gu</surname>
<given-names>Yunjuan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1192333/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Gang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/456527/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Xia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2621824/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Histology and Embryology</institution>, <institution>Medical School of Nantong University</institution>, <addr-line>Nantong</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Endocrinology</institution>, <institution>Affiliated Hospital of Nantong University</institution>, <institution>Nantong University</institution>, <addr-line>Nantong</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Nantong Xingzhong Cell Engineering Co. Ltd</institution>, <addr-line>Nantong</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1225154/overview">Mar&#xed;a Delgado Esteban</ext-link>, University of Salamanca, Spain</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2693885/overview">Xiaoqing Zhang</ext-link>, Tongji University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1284650/overview">Susmita Sil</ext-link>, University of Nebraska Medical Center, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1477745/overview">Yuqing Yan</ext-link>, West Virginia University, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Xia Chen, <email>ylchenxia@ntu.edu.cn</email>; Gang Chen, <email>chengang6626@ntu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1365928</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>01</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Qin, Zhou, Yu, Ye, Wang, Zhou, Gu, Chen and Chen.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Qin, Zhou, Yu, Ye, Wang, Zhou, Gu, Chen and Chen</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Neuroinflammation plays a key role in the progression of secondary brain injury after ischemic stroke, and exosomes have been increasingly recognized to eliminate inflammatory responses through various mechanisms. This study aimed to explore the effect and possible mechanism of human umbilical vein endothelial cells derived exosomes (H-EXOs) on neuroinflammation. We established a transient middle cerebral artery occlusion/reperfusion (tMCAO/R) in male rats and oxygen-glucose-deprivation/reoxygenation (OGD/R) model in cultured neurons to mimic secondary brain injury after ischemic stroke <italic>in vivo</italic>. H-EXOs were administered at the same time of reperfusion. Results showed that the production of pro-inflammatory cytokines TNF-&#x3b1;, IL-1&#x3b2;, and IL-6, and the transcription factor Kr&#xfc;ppel-like factor 14 (KLF14) were significantly increased both in rat brain tissue and cultured neural cells after ischemic-reperfusion (I/R) injury. H-EXOs treatment significantly improved the cultured cell viability, reduced infarct sizes, mitigated neurobehavioral defects, and alleviated the expression of pro-inflammatory cytokines compared with the control group, indicating that H-EXOs exerted anti-inflammatory effect against I/R injury. Further studies revealed that the anti-inflammatory effect of H-EXOs could be weakened by small-interfering RNA (siKLF4) transfection. KLF14 was a protective factor produced during cerebral ischemia-reperfusion injury. In conclusion, H-EXOs protect neurons from inflammation after I/R injury by enhancing KLF14 expression.</p>
</abstract>
<kwd-group>
<kwd>HUVEC</kwd>
<kwd>exosomes</kwd>
<kwd>brain ischemic</kwd>
<kwd>KLF14</kwd>
<kwd>inflammation</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Neuropharmacology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Ischemic stroke is often caused by vascular blockage. The most common treatments for ischemic injuries rely on the immediate restoration of blood flow which is limited by the narrow time frame and invasiveness of the surgical procedures (<xref ref-type="bibr" rid="B40">Prabhakaran et al., 2015</xref>). Additionally, the subsequent reperfusion of the blood flow can lead to a secondary injury, termed as reperfusion injury, mainly owing to a series of pathological changes induced by ischemia-reperfusion, including blood-brain barrier (BBB) disruption, increased excitotoxicity, oxidative stress, inflammation, and mitochondrial dysfunction (<xref ref-type="bibr" rid="B36">Parvez et al., 2022</xref>). Of these events, the inflammatory reaction occurs initially in the acute phase and continues to escalate during the course of the injury. The main effects of inflammation are the destruction of the BBB, damage to neurons, and acceleration of vascular aging, all of which can exacerbate brain tissue damage and are related to the severity and prognosis of stroke (<xref ref-type="bibr" rid="B22">Kunz et al., 2010</xref>; <xref ref-type="bibr" rid="B57">Yang et al., 2021</xref>). In the clinical setting, the current treatment strategy for ischemic stroke relies on thrombolysis. However, thrombolytic therapy itself exacerbates the occurrence of inflammation and may cause greater damage to patients with ischemic stroke. Thus, the inhibition of inflammation is of great significance for the treatment of ischemic stroke (<xref ref-type="bibr" rid="B52">Wong and Crack, 2008</xref>; <xref ref-type="bibr" rid="B43">Shi et al., 2021</xref>).</p>
<p>Neuroinflammation participates in the whole pathophysiological process of cerebral ischemia (<xref ref-type="bibr" rid="B20">Kelly et al., 2018</xref>). Numerous studies have shown that stem cells can reduce delayed neuronal degeneration by inhibiting inflammatory responses. The neural factors secreted by stem cells can also regulate the inflammatory response after an infarction. Using stem cell transplantation to treat cerebral infarction may promote endogenous nerve regeneration and the self-repair of brain tissue. But stem cells have heterogeneity, which directly affects the therapeutic effect. Furthermore, some stem cell therapies have safety risks, mainly including tumorigenicity, abnormal immune response, and unexpected differentiation. Compared to stem cells, exosome-based cell-free therapies are gaining more attention because they effectively avoid the risks of low survival, strong immune rejection, and high mutational tumorigenicity associated with direct stem cell therapy (<xref ref-type="bibr" rid="B48">Verweij et al., 2019</xref>). Exosome is an extracellular vesicle with a diameter of about 40&#x2013;140&#xa0;nm that transmits biological information between cells, owing to its special structure and contents (including cell surface proteins and various components within cells such as DNA, RNA, lipids, metabolites, etc.) (<xref ref-type="bibr" rid="B10">Ferguson et al., 2018</xref>; <xref ref-type="bibr" rid="B19">Kalluri and LeBleu, 2020</xref>). Given their excellent biological characteristics, including biocompatibility, stability, low toxicity, low immunogenicity, and efficient exchange of molecular cargos, exosomes can be potentially applied for disease treatment (<xref ref-type="bibr" rid="B38">Patel et al., 2021</xref>; <xref ref-type="bibr" rid="B49">Wan et al., 2022</xref>; <xref ref-type="bibr" rid="B53">Xie et al., 2022</xref>). Recent studies demonstrated that exosomes derived from berberine-pretreated astrocytes, bone marrow-derived mesenchymal stem cells, endothelial progenitor cells, and neural stem cells can suppress neuroinflammation after stroke through different mechanisms (<xref ref-type="bibr" rid="B29">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="B8">Ding et al., 2023</xref>; <xref ref-type="bibr" rid="B35">Pan et al., 2023</xref>; <xref ref-type="bibr" rid="B39">Peng et al., 2023</xref>). Studies suggested that exosomes have protective effects on the brain by inhibiting inflammatory responses following ischemic stroke and have broad application prospects.</p>
<p>The exosomes employed herein were derived from human umbilical vein endothelial cells (HUVECs), which are primary cells isolated from umbilical veins. HUVECs offer several advantages, such as easy isolation, a sufficient source, low immunogenicity, strong proliferative ability, and no ethical disputes. The blood in umbilical venous is usually arterial blood, which contains a certain amount of oxygen and nutrients (<xref ref-type="bibr" rid="B55">Yamaguchi et al., 1996</xref>). In addition, HUVECs synthesize and secrete various cytokines and chemicals which can regulate vasodilation and contraction, platelet aggregation, coagulation, etc. (<xref ref-type="bibr" rid="B56">Yamaguchi et al., 1998</xref>; <xref ref-type="bibr" rid="B58">Yildirim et al., 2005</xref>; <xref ref-type="bibr" rid="B24">Li et al., 2006</xref>). Overall, it indicates that exosomes derived from HUVEC (simply called H-EXOs) can be potential employed for ischemic stroke treatment, but more research are needed to strengthen that. Herein, we aim to explore the effect and underlying mechanism of H-EXOs on inflammation after reperfusion in cerebral ischemic injury.</p>
<p>In the present study, we performed transient right middle cerebral artery occlusion/reperfusion (tMCAO/R) model in rats and oxygen-glucose deprivation/re-oxygenation (OGD/R) model in cultured neural cells to simulate brain injury with I/R. We found that H-EXOs significantly protected the brain from ischemic damage by suppressing the production of pro-inflammatory factors and the phosphorylation of the P65 subunit of the nuclear factor kappa B (NF-&#x3ba;B). We also found that the H-EXOs have anti-inflammatory effects, at least in part, via upregulating the transcription factor Kr&#xfc;ppel-like factor 14 (KLF14). Together, our findings provide a new experimental evidence of the pathophysiological mechanism underlying ischemic stroke, and highlight new potential targets for the prevention and treatment of ischemic brain injury.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<p>The materials and reagents used in the experiment are detailed in <xref ref-type="sec" rid="s11">Supplementary Table S1</xref>.<list list-type="simple">
<list-item>
<p>1. Cell Culture: Mouse hippocampal neuronal HT22 cell line and human umbilical vein endothelial cells (HUVEC) were cultured in Dulbecco&#x2019;s modified Eagle&#x2019;s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin at 37&#xa0;&#xb0;C in a 5% CO<sub>2</sub> incubator. The culture medium was changed daily to maintain cell viability.</p>
</list-item>
<list-item>
<p>2. Extraction and Identification of Exosomes: The exosomes were isolated through size exclusion chromatography (SEC) and subsequently gathered via ultracentrifugation. In brief, a chromatography column filled with porous gel particles was used for size-exclusion chromatography. Samples passed through the column, and substances larger than the gel particle pore size were unable to enter the pores and were washed out through the gaps between the gel particles. Substances smaller than the gel particle pore size entered the interior pores. In exosomes isolation, the larger-sized exosomes were eluted first, while smaller-sized free proteins and impurities took longer to elute, effectively separating them from the exosomes, then the pellets were collected by ultracentrifugation at 120,000&#xa0;g for 90&#xa0;min.</p>
</list-item>
<list-item>
<p>3. Exosome fluorescence labeling and internalization experiments: The exosomes were labeled using the PKH26 Red Fluorescent Probe as per the provided instructions (<xref ref-type="bibr" rid="B27">Liu et al., 2023</xref>). Subsequent tail vein injections in MCAO/R-injured rats were performed using fluorescently labeled exosomes. Brain sections were taken 4&#xa0;h later. HT22 neuronal cells were cultured on circular slides. Then, luorescently labeled exosomes were added to the well for 12&#xa0;h. Make a glass coverslip mounted on a glass microscope slide. Fluorescent images were taken using confocal microscopy.</p>
</list-item>
<list-item>
<p>4. Establishment of the OGD/R injured model: The OGD/R injured model was created using the methods previously described with some modifications (<xref ref-type="bibr" rid="B51">Wang et al., 2018</xref>). HT22 cells were cultured with 1&#xa0;mM Na2S2O4 (oxygen scavenger) in sugar-free DMEM for 4&#xa0;h, then subjected reperfusion for 12&#xa0;h to construct a stable OGD/R-injured model.</p>
</list-item>
<list-item>
<p>5. Detection of cell viability: 3 - (4,5 - dimethylthiazol - 2 - yl) &#x2212;2,5 - diphenyl - 2H - tetrazolium bromide (MTT) test was used to assess cell viability. The cultured cells were cultured in a 96-well plate with a density of 4&#xd7;10<sup>3</sup> cells per well, then exposed to OGD/R treatment and other relevant protocol. 10&#xa0;&#x3bc;L of 0.5% MTT solution prepared from MTT powder was added to each well and incubated for 4&#xa0;h in a CO<sub>2</sub> incubator. Next, a 100&#xa0;&#x3bc;L solution of 10% SDS, which was made from SDS powder, was introduced into each well of the culture. This process was allowed to proceed for a duration of 12&#xa0;h, following which the absorbance at 570&#xa0;nm was determined using an enzyme meter.</p>
</list-item>
<list-item>
<p>6. Cell Transfection: The transfection of siRNA was conducted by employing the Lipofectamine 2000 reagent in accordance with the guidelines provided by the manufacturer. KLF14 siRNA and negative controls were obtained from Ribobio. The sequences used for cell transfection are as follows: 5&#x2032;- GCA&#x200b;ACA&#x200b;AGG&#x200b;CCT&#x200b;ACT&#x200b;ACA&#x200b;A -3&#x2032;. KLF14 overexpression lentivirus was purchased from Genechem, and transfection was performed according to the manufacturer&#x2019;s instructions.</p>
</list-item>
<list-item>
<p>7. MCAO/R Model: Adult male SD rats used in this study, weighted 250&#x2013;280&#xa0;g were obtained from the Model Animal Research Center of Nantong University and received ethical approval for animal experimentation (No. S20231219-001). Premade poly-L-lysine-coated sutures were purchased from Cionotech. In brief, rats were anesthetized with isoflurane, and after skin preparation, a minor surgical cut was performed along the centerline of the neck. The right common carotid artery was exposed, and a small cut was made in it. The suture was inserted through this cut, advanced into the internal carotid artery, and ultimately reached the middle cerebral artery, where it was secured using a pre-tied ligature. After 2&#xa0;h of blockage, the rats were followed by reperfusion for 24&#xa0;h. During the surgery, the rectal temperature of the rats was maintained at 36.5&#xb0;C &#xb1; 0.5&#xb0;C, and their respiration and heartbeat were monitored. Follow-up experiments were conducted using rats with Longa behavioral scores of 1&#x2013;3 (<xref ref-type="bibr" rid="B33">Mahemuti et al., 2023</xref>).</p>
</list-item>
<list-item>
<p>8. Measurement of Cerebral Infarct Volume: 2, 3, 5-triphenyltetrazolium chloride (TTC) staining was performed 24&#xa0;h after MCAO surgery. Brains from each group of rats were rapidly put on ice and sliced into approximately 2&#xa0;mm-thick sections. These slices were then placed in a 2% TTC solution prepared with TTC powder at 37&#xa0;&#xb0;C for 30&#xa0;min. Normal brain tissue appeared red, while ischemic brain tissue appeared white (<xref ref-type="bibr" rid="B46">Tang et al., 2024</xref>). The total area of the infarct in each section was calculated and presented as a percentage of the volume of the unaffected area: infarct volume (%) &#x003D; [(volume of the healthy side hemisphere - volume of the uninjured area on the affected side)/volume of the healthy side hemisphere] &#xd7; 100%.</p>
</list-item>
<list-item>
<p>9. Longa Score: 24&#xa0;h after completion of the MCAO model, the examiner used the Longa behavioral test to evaluate the neurological impairment score (<xref ref-type="bibr" rid="B30">Longa et al., 1989</xref>). The Longa Score was evaluated using a scale ranging 0&#x2013;5. A score of 0 indicated the absence of any neurological deficits. A score of 1 indicated the inability to fully extend the left forepaw. Circling to the left when walking was assigned a score of 2. Falling to the left while walking corresponded to a score of 3. A score of 4 indicated the inability to walk spontaneously and a lack of consciousness. Higher scores on this scale were indicative of more severe neurological damage.</p>
</list-item>
<list-item>
<p>10. Nissl Staining: Morphology and distribution of neurons in the ischemic penumbra following 24&#xa0;h post-reperfusion were observed using cresyl violet (Nissl) staining (<xref ref-type="bibr" rid="B23">Li et al., 2023</xref>). The experimental procedure strictly followed the manufacturer&#x2019;s instructions for cresyl violet dye. Observations and photographs were made using a Leica microscope.</p>
</list-item>
<list-item>
<p>11. RT-qPCR: Total RNA was extracted from cells and brains using TRIzol reagent. Reverse transcription was performed with RT-qPCR according to the HiScript II Q RT SuperMix for qPCR (&#x002B;gDNA wiper) kit with the Taq Pro Universal SYBR qPCR Master Mix, reverse transcription with RT-qPCR was performed. RT-qPCR reactions were run on a Bio-Rad CFX96. The 18S gene was considered as an internal reference. The relative expression levels were assessed using the 2<sup>&#x2212;&#x394;&#x394;CT</sup> method. Primer sequences are detailed in <xref ref-type="sec" rid="s11">Supplementary Table S2</xref>.</p>
</list-item>
<list-item>
<p>12. Western blot: The samples underwent separation through either 10% or 12.5% SDS-PAGE gel electrophoresis and were subsequently moved into PVDF membranes. Following this, the membranes were immersed in 5% skim milk for a duration of 2&#xa0;h and then probed with anti-CD63 mouse monoclonal, anti-TSG101 rabbit monoclonal, rabbit monoclonal anti-KLF14, anti-NF-&#x3ba;B p65 rabbit monoclonal, anti-phosphorylation NF-&#x3ba;B p65 rabbit monoclonal, and anti-&#x3b2;-actin mouse monoclonal at 4&#xa0;&#xb0;C overnight. Subsequently, membranes were incubated with anti-mouse IgG-HRP or anti-rabbit IgG-HRP for 2&#xa0;h at room temperature. Protein signals were detected using a highly sensitive ECL chemiluminescence substrate and analyzed with a Tanon 5,200 Multi system.</p>
</list-item>
<list-item>
<p>13. Statistical Analysis: The data is displayed as mean &#xb1; SD, unless specified otherwise. Statistical analyses were employed by GraphPad Prism. Statistical analysis among more groups were determined by One-way ANOVA. <italic>p</italic>-value less than 0.05 was considered statistically significant.</p>
</list-item>
</list>
</p>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<p>
<list list-type="simple">
<list-item>
<p>1. Characterization of H-EXOs</p>
</list-item>
</list>
</p>
<p>Exosomes are defined as small membrane vesicles with a diameter of 40&#x2013;140&#xa0;nm and a circular shape (<xref ref-type="bibr" rid="B44">Simons and Raposo, 2009</xref>). H-EXOs in this study are within a median diameter of 118&#xa0;nm and the size distribution is shown in <xref ref-type="fig" rid="F1">Figure 1A</xref>. The concentration of this isolated exosomes are about 1.1&#xd7;10<sup>14</sup> particles/mL. Exosomes should express transmembrane proteins such as CD63 and endosome proteins such as TSG101 (<xref ref-type="bibr" rid="B31">L&#xf6;tvall et al., 2014</xref>), and we confirmed that our isolated exosomes H-EXOs expressed both CD63 and TSG101, meanwhile our results showed that the negative control Calnexin was not expressed in H-EXOs (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Purified H-EXOs were examined using transmission electron microscopy (TEM), which revealed their typical cup-shaped and clear lipid bilayer structure (<xref ref-type="fig" rid="F1">Figure 1C</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Characterization of H-EXOs and their internalization by cells. H-EXOs can enter MCAO/R-treated brain tissue and can be taken up by HT22 cells. <bold>(A)</bold> NTA of H-EXOs. <bold>(B)</bold> Western blot detection of exosome markers CD63, TSG101 and negative control Calnexin. <bold>(C)</bold> TEM images of exosomes of H-EXOs. Scale bar, 50&#xa0;nm. <bold>(D)</bold> Immunofluorescence staining showing PKH26-labeled exosomes (red) in brain slice of MCAO-R injured rat. Nuclei stained blue by DAPI. Scale bar, 50&#xa0;&#xb5;m. <bold>(E)</bold> Immunofluorescence staining showing PKH26-labeled exosomes (red) in HT22 cells. Cells nucleus were stained with DAPI (blue). Scale bar, 50&#xa0;&#xb5;m.</p>
</caption>
<graphic xlink:href="fphar-15-1365928-g001.tif"/>
</fig>
<p>Because the interaction between H-EXOs and their target tissues or cells is important for the therapeutic effect (<xref ref-type="bibr" rid="B47">van Niel et al., 2018</xref>), so we tested whether H-EXOs are taken up by ischemia-reperfusion injured brain tissues of rats and HT22 cells. HT22 is a sub-line derived from parent HT4 cells that were originally immortalized from cultures of primary mouse hippocampal neurons, which is widely used as an ideal hippocampal neuronal model (<xref ref-type="bibr" rid="B60">Zaulyanov et al., 1999</xref>; <xref ref-type="bibr" rid="B37">Pascual et al., 2012</xref>). MCAO/R-injured rats were injected with 1&#xa0;mL PKH26-labeled H-EXOs from tail vein at the same time of reperfusion. Four hours later, the rats were sacrificed and the brain tissues were sampled. Confocal microscopy analysis revealed no red fluorescence in the brain tissue sections of the control rats. However, red fluorescence was evident in the brain tissue sections of the rats from the experimental group (PKH26-labeled H-EXO). Thus, PKH26-labeled H-EXOs could reach the brain tissue of rats after MCAO/R injury (<xref ref-type="fig" rid="F1">Figure 1D</xref>). Furthermore, the PKH26-labeled H-EXOs were added to the wells of HT22 cells for 12&#xa0;h. The labeled exosomes were found in HT22 cells and located in the cytoplasm, indicating their complete internalization. As showed in <xref ref-type="fig" rid="F1">Figure 1E</xref>, almost all HT22-cells became positive for PKH26. These results suggested that our isolated H-EXOs are able to enter the penumbra region of the cerebral cortex of rats after tMCAO operation and be taken up by cultured HT22 cells.</p>
<p>Taken together, we successfully isolated H-EXOs for the following study.<list list-type="simple">
<list-item>
<p>2. H-EXOs significantly inhibited the production of pro-inflammatory molecules and protected neurons from MCAO/R injury in rats</p>
</list-item>
</list>
</p>
<p>First, to validate the protective effect of H-EXOs treatment against brain ischemia, we performed MCAO surgery in rats, as previously described. Ten rats were randomly assigned to the sham (received the same procedure as MCAO but without artery occlusion), MCAO/R, or MCAO/R &#x002B; H-EXOs group. After 24&#xa0;h of reperfusion, neurological deficits were examined by the Longa&#x2019;s score. We found that the MCAO/R group had a score of about 3, while the group treated with H-EXOs had neurological scores between 1 and 2 (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Subsequently, TTC staining of the rat brain was performed to determine infarct volume. As shown in <xref ref-type="fig" rid="F2">Figure 2B</xref>, the red area is normal brain tissue, while the white area is infarcted due to ischemia. The infarct area in the MCAO/R group accounted for about 40% of the total brain volume, while that in the H-EXOs group accounted for about 20% of the total brain volume (<xref ref-type="fig" rid="F2">Figure 2C</xref>), indicating that H-EXOs remarkably reduced cerebral infarction volume. Previous studies have suggested that ischemic-vulnerable areas include the hippocampus, cortex, thalamus, and other parts. Among various types of cells, neurons have the highest sensitivity to ischemia. In order to confirm whether H-EXOs could reduce neuronal damage from MCAO/R injury, morphological changes in neurons were investigated by Nissl staining. We found that the MCAO/R group had collapsed neuronal cell structure, the presence of vacuoles around cells, nuclear condensation, and reduced Nissl bodies. In contrast, most of the neurons from the H-EXO-treated group showed a relatively intact morphology, with only a few cells displaying nuclear condensation and reduced Nissl bodies (<xref ref-type="fig" rid="F2">Figure 2D</xref>). Similar changes were also observed in the CA1 region of the rat hippocampus, which is enriched with neurons (<xref ref-type="fig" rid="F2">Figure 2E</xref>). All the above results suggested that H-EXOs can protect neurons from ischemia-reperfusion injury.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>H-EXOs attenuate brain damage and inhibit inflammation in the right cortical ischemic penumbral areas of MCAO2h/R24h rats. <bold>(A)</bold> Neurological deficit scores of rats with MCAO/R injury in different groups. H-EXOs were administrated at the time of reperfusion. Neurological deficits were evaluated using the Longa score 24h after reperfusion (n &#x003D; 10). <bold>(B)</bold> Coronal brain sections were stained by TTC in the sham group, MCAO/R group, and H-EXOs group, along with quantification of infarct volumes <bold>(C)</bold> (n &#x003D; 5). <bold>(D)</bold> Microscopic images of Nissl-stained rat brain cortex. Scale bar, 100&#xa0;&#x3bc;m. <bold>(E)</bold> Microscopic images of Nissl-stained rat brain hippocampal CA1 region. Scale bar, 100&#xa0;&#x3bc;m. <bold>(F&#x2013;H)</bold> RT-qPCR detect the level of TNF-&#x3b1;, IL-1&#x3b2;, and IL-6 in the ischemic penumbral area of the right cerebral cortex of MCAO2h/R24h rats after tail vein injection with H-EXOs for 24h (n &#x003D; 5). <bold>(I)</bold> Western blot detection of NF&#x3ba;B P65 and PP65 levels in the ischemic penumbral area of the right cerebral cortex of MCAO2h/R24h rats after tail vein injection of H-EXOs for 24h. <bold>(J)</bold> Quantification of western blot results in <bold>(J)</bold> (n &#x003D; 3). The data underwent analysis using a one-way ANOVA method. &#x2a;<italic>p</italic> &#x003c; 0.05, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x003c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-15-1365928-g002.tif"/>
</fig>
<p>Next, to explore the underlying mechanisms of the protective effects of H-EXOs on rat brain tissues during ischemic-reperfusion injury, we assessed the expression of pro-inflammatory cytokines IL-1&#x3b2;, IL-6, and TNF-&#x3b1; in penumbra areas of cerebral cortex of MCAO/R rats by RT-qPCR. The results showed that the mRNA levels of IL-1&#x3b2;, IL-6, and TNF-&#x3b1; in rat brains after MCAO/R injury were apparently higher than those in the brains of the sham-operated rats, and H-EXOs treatment reduced the increased levels of these factors (<xref ref-type="fig" rid="F2">Figures 2F&#x2013;H</xref>). The NF-&#x3ba;B signaling pathway is an important inflammation pathway (<xref ref-type="bibr" rid="B61">Zhao et al., 2021</xref>). When stroke occurs, the NF-&#x3ba;B inflammatory signaling pathway is activated to stimulate the phosphorylation of P65 protein to p-P65, and then p-P65 enters the nucleus to further induce the release of inflammatory factors including TNF-&#x3b1;, IL-1&#x3b2; and IL-6 etc. (<xref ref-type="bibr" rid="B45">Singh and Singh, 2020</xref>). Therefore, we examined the phosphorylation of P65 in the penumbra region of the cerebral cortex in rats. The level of P65 phosphorylation was significantly increased after MCAO/R but suppressed by H-EXOs (<xref ref-type="fig" rid="F2">Figures 2I, J</xref>). In summary, H-EXOs can effectively alleviate the production of inflammatory factors and protect neurons in brain tissue of rats from MCAO/R injury.<list list-type="simple">
<list-item>
<p>3. Internalized H-EXOs dramatically reduced the production of pro-inflammatory factors and protected cultured HT22 neuronal cells from OGD/R injury</p>
</list-item>
</list>
</p>
<p>To confirm the protective effect of H-EXOs on injured neuronal cells, HT22 cells were cultured with conditional medium which contains 1&#xa0;mM Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> and sugar-free medium without FBS for 2&#xa0;h and then cultured in DMEM medium with 10% FBS for 12&#xa0;h to construct the OGD/R model (<xref ref-type="bibr" rid="B11">Gao et al., 2020</xref>). To verify the therapeutic effect of H-EXOs on OGD/R, OGD/R-treated HT22 cells were incubated with different dosages of H-EXOs. As shown in <xref ref-type="fig" rid="F3">Figure 3A</xref>, HT22 cell viability was significantly decreased about 50% in the OGD/R group compared with the control group. 1&#xd7;10<sup>12</sup> particles/mL of H-EXOs had no obvious therapeutic effect, and 5&#xd7;10<sup>12</sup> particles/mL of H-EXOs significantly improved cell viability, but there was no better therapeutic effect when the dosage reached 1&#xd7;10<sup>13</sup> particles/mL. Therefore, the optimal effective dosage of H-EXOs was 5&#xd7;10<sup>12</sup> particles/mL. RT-qPCR results also confirmed that OGD/R injury significantly increased the production of TNF-&#x3b1;, IL-1&#x3b2;, and IL-6, which were apparently downregulated in the H-EXOs treated-cells (<xref ref-type="fig" rid="F3">Figures 3B&#x2013;D</xref>). We also measured the P65/p-P65 protein levels in HT22 cells and found that H-EXOs treatment markedly reduced the protein expression of phosphorylated P65 (p-P65) induced by OGD/R (<xref ref-type="fig" rid="F3">Figures 3E, F</xref>). These results indicated that H-EXOs inhibit OGD/R-induced inflammatory responses in HT22 cells.<list list-type="simple">
<list-item>
<p>4. The expression of KLF14 was increased by H-EXOs, which turns out to be a protective factor produced during cerebral ischemia-reperfusion injury</p>
</list-item>
</list>
</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>H-EXOs prevent cultured HT22 neuronal cells from OGD/R injury. <bold>(A)</bold> The therapeutic effects of different doses of H-EXOs were tested after OGD4h/R12h by using MTT assay (n &#x003D; 6). <bold>(B&#x2013;D)</bold> RT-qPCR detect the change of TNF-&#x3b1;, IL-1&#x3b2;, and IL-6 mRNA expression in HT22 cells after OGD/R injury (n &#x003D; 5). <bold>(E)</bold> Western blot detection of NF&#x3ba;B P65 and p-P65 level in HT22 cells caused by OGD/R injury and its quantification in <bold>(F)</bold> (n &#x003D; 3). The data underwent analysis using a one-way ANOVA method. &#x2a;<italic>p</italic> &#x003c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x003c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x003c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-15-1365928-g003.tif"/>
</fig>
<p>Transcription factor KLF14 is a member of the KLF family and exerts anti-inflammatory effects in many diseases, such as sepsis, atherosclerosis, and immune-mediated hepatic injury, etc. We wonder whether the anti-inflammatory effects of H-EXOs are related to KLF14. First, we tested the expression of KLF14 in the brain tissue of rats and cultured HT22 cells suffering from I/R injury. The results of RT-qPCR and Western blot indicated that the expression of KLF14 in the OGD/R group was significantly increased compared with that in the control group, and the expression of KLF14 in the H-EXOs group was further increased, about a 1.5-fold increase compared with the OGD/R group (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;C</xref>). Similar results were observed <italic>in vivo</italic> experiments. H-EXOs significantly increased the levels of KLF14 mRNA and protein in the ischemic penumbra region of the cerebral cortex, respectively, about 2.5-fold and 1.5-fold compared with the MCAO/R group (<xref ref-type="fig" rid="F4">Figures 4D&#x2013;F</xref>). Summarizing the results given above, KLF14 expression was significantly increased in brain tissue and cultured cells after injury, and further increased with H-EXOs treatment.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>H-EXOs can induce KLF14 expression which is an endogenous regulator involved in the pathophysiology of the inflammatory response in ischemic stroke. <bold>(A)</bold> RT-qPCR analysis KLF14 mRNA change level of HT22 cells caused by OGD/R injury (n &#x003D; 5). <bold>(B)</bold> Western blot analysis of KLF14 protein expression in HT22 cells after injury. <bold>(C)</bold> Statistical analysis of <bold>(B)</bold> (n &#x003D; 3). <bold>(D)</bold> RT-qPCR analysis of KLF14 level in the right cortical ischemic penumbral areas of MCAO2/R24h rats after H-EXOs treatment (n &#x003D; 5). <bold>(E)</bold> Western blot detection of KLF14 level in the right cortical ischemic penumbral areas of MCAO2h/R24h rats after H-EXOs treatment and its quantification in <bold>(F)</bold> (n &#x003D; 3). <bold>(G)</bold> RT-qPCR detection of KLF14 expression in HT22 cells treated with LVs-KLF14 and LVs-NC after OGD4h/R12h (n &#x003D; 5). <bold>(H)</bold> Western blot detection of KLF14 expression in HT22 cells after transfection with LVs-KLF14 and LVs-NC after OGD4h/R12h and its quantification in <bold>(I)</bold> (n &#x003D; 3). <bold>(J)</bold> MTT assay in HT22 cells treated with LVs-KLF14 and LVs-NC after OGD4h/R12h (n &#x003D; 6). <bold>(K&#x2013;M)</bold> RT-qPCR detect the TNF-&#x3b1;, IL-6, and IL-1&#x3b2; expression level of HT22 cells treated with LVs-KLF14 and LVs-NC after OGD4h/R12h (n &#x003D; 5). (N) RT-qPCR test KLF14 expression level in HT22 cells treated with siKLF14 and siNC after OGD4h/R12h (n &#x003D; 5). <bold>(O)</bold> Western blot detection of KLF14 expression in HT22 cells after siKLF14 and siNC transfected after OGD4h/R12h and its quantification in <bold>(P)</bold> (n &#x003D; 3). <bold>(Q)</bold> Cell viability of HT22 cells treated with siKLF14 and siNC after OGD4h/R12h were detected using MTT assay. (n &#x003D; 6). <bold>(R&#x2013;T)</bold> RT-qPCR detect TNF-&#x3b1;, IL-6 and IL-1&#x3b2; change level in HT22 cells treated with siKLF14 and siNC after OGD4h/R12h (n &#x003D; 5). The data underwent analysis using a one-way ANOVA method. &#x2a;<italic>p</italic> &#x003c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x003c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x003c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-15-1365928-g004.tif"/>
</fig>
<p>Next, to confirm whether the increase of KLF14 expression is potentially a protective factor or a pathogenic factor, we regulated the expression of KLF14 in HT22 cells by using the lentivirus vector KLF14 (LVs-KLF14) for overexpressing and a small-interfering RNA (siKLF4) for downregulation. After transfection, we detected the HT22 cell viability and the expression of pro-inflammatory factors. Compared with the LVs-NC group, the expression levels of KLF14 mRNA and protein significantly increased about 2-fold both in the normal cultured and OGD/R-injured HT22 cell groups with LVs-KLF14, indicating that overexpressing KLF14 transfection was successful (<xref ref-type="fig" rid="F4">Figures 4G&#x2013;I</xref>). Even though overexpressing KLF14 did not affect normal cell viability, the survival of OGD damaged cells was promoted by KLF14 overexpression (<xref ref-type="fig" rid="F4">Figure 4J</xref>). Meanwhile, the results of RT-qPCR showed that there was no significant difference in the expression levels of pro-inflammatory factors <italic>TNF-&#x3b1;</italic>, <italic>IL-1&#x3b2;</italic>, and <italic>IL-6</italic> between the LVs-KLF14 group and the LVs-NC group under non-OGD/R culture conditions (<xref ref-type="sec" rid="s11">Supplementary Figure S1A</xref>). However, after OGD/R treatment, the expression level of pro-inflammatory factors in the LVs-KLF14 group was dramatically lower over 50% than that in the LVs-NC group (<xref ref-type="fig" rid="F4">Figure 4K&#x2013;M</xref>). These results suggested that overexpressing KLF14 can suppress the expression of pro-inflammatory factors. To further confirm the anti-inflammatory effect of KLF14, we also used a small-interfering RNA (siKLF4) to repress KLF14 expression in HT22 cells, and the cells treated with siKLF14 exhibited lower KLF14 mRNA and protein expression (about 65% reduction) both in the normal cultured and OGD/R-injured HT22 cells groups (<xref ref-type="fig" rid="F4">Figure 4N&#x2013;P</xref>). The results of the MTT assay demonstrated that the cell viability of siKLF14 transfected cells was lower than that of siNC transfected cells (about 15% reduction). After OGD/R injury, the cell viability of siKLF14 transfected cells was much lower than that of the siNC transfected group (about 30% reduction, <xref ref-type="fig" rid="F4">Figure 4O</xref>). The results of RT-qPCR exhibited no significant difference in the expression levels of pro-inflammatory factors from the siKLF14 group and the siNC group (<xref ref-type="sec" rid="s11">Supplementary Figure S1B</xref>). However, after OGD/R, cells transfected with siKLF14 showed higher levels of pro-inflammatory factors than the cells transfected with siNC (about two to three fold increase, <xref ref-type="fig" rid="F4">Figure 4P</xref>).</p>
<p>In conclusion, KLF14 is a protective factor that is produced during cerebral ischemia-reperfusion injury. H-EXOs treatment increased KLF14 expression after I/R injury.<list list-type="simple">
<list-item>
<p>5. H-EXOs played anti-inflammatory roles by upregulating KLF14</p>
</list-item>
</list>
</p>
<p>To investigate whether KLF14 was related to the anti-inflammatory effects of H-EXOs, we regulated KLF14 expression with siKLF4 transfection in OGD/R-injured HT22 neural cells and then incubated them with H-EXOs. We found that, with siKLF14 treatment, the expression of KLF14 mRNA and protein induced by H-EXOs separately decreased to 60% and 40%, compared with the siNC treatment (<xref ref-type="fig" rid="F5">Figures 5A&#x2013;C</xref>). To better confirm whether KLF14 is involved in mediating the anti-inflammation effect of H-EXOs, we tested cell viability by the MTT assay and pro-inflammatory factors expression by RT-qPCR. The results showed that siKLF4 transfected cells with H-EXOs treatment presented cell viability decreased to 85% and pro-inflammatory cytokines expression increased to 2.5-fold of H-EXO-treated siNC cells (<xref ref-type="fig" rid="F5">Figures 5D&#x2013;G</xref>). Collectively, H-EXOs exerted anti-inflammatory effects in neurons after ischemic stroke via upregulating the expression of KLF14.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Interference with KLF14 alleviates H-EXOs-mediated anti-inflammatory effects. <bold>(A)</bold> RT-qPCR detection of KLF14 levels in HT22 neuronal cells after treatment with OGD/R &#x002B; H-EXOs &#x002B; siNC or OGD/R &#x002B; H-EXOs &#x002B; siKLF4 (n &#x003D; 5). -- <bold>(B)</bold> Western blot detection of KLF14 levels in HT22 neuronal cells after treatment with OGD/R &#x002B; H-EXOs &#x002B; siNC or OGD/R &#x002B; H-EXOs &#x002B; siKLF4 and its quantification in <bold>(C)</bold> (n &#x003D; 3). <bold>(D)</bold> MTT assay assessing cell viability in HT22 cells after treatment with siKLF4 and siNC following OGD4h/R12h and H-EXOs treatment (n &#x003D; 5). <bold>(E&#x2013;G)</bold> RT-qPCR detection of TNF-&#x3b1;, IL-1&#x3b2;, and IL-6 mRNA expression in HT22 cells after treatment with siKLF4 and siNC following OGD4h/R12h and H-EXOs treatment (n &#x003D; 5). All the data were analyzed by one&#x2010;way ANOVA. &#x2a;<italic>p</italic> &#x003c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x003c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x003c; 0.001.</p>
</caption>
<graphic xlink:href="fphar-15-1365928-g005.tif"/>
</fig>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Inflammatory response is a hallmark of ischemic stroke onset, especially after reperfusion, which initiates rapidly and lasts for a long time, thereby providing a long window period for treatment (<xref ref-type="bibr" rid="B18">Justin et al., 2018</xref>; <xref ref-type="bibr" rid="B20">Kelly et al., 2018</xref>). Therefore, understanding the mechanism of post-stroke inflammation and regulating it will be a highly potential stroke treatment strategy (<xref ref-type="bibr" rid="B43">Shi et al., 2021</xref>). An increasing number of studies nowadays demonstrated the vital role of exosomes in maintaining the ischemic injured brain structure and function, given their unique lipid bilayer structure and diverse cargos (<xref ref-type="bibr" rid="B14">He et al., 2018</xref>). Here, we showed that H-EXOs protected the brain from tMCAO/R injury in rats and OGD/R injury in cultured neuronal cells through the suppression of the inflammatory response, suggesting that H-EXOs is a promising therapeutic biological agent for I/R injury. Although several recent studies have indicated the potential therapeutic effects of exosomes derived from post-ischemic HUVECs in the treatment of ischemic stroke, more studies are warranted to explore new directions. Some researchers believe that the different times of ischemic preconditioning may result in varying metabolomics differences (<xref ref-type="bibr" rid="B2">Baranovicova et al., 2020</xref>). The role of H-EXOs without pretreatment remains unconfirmed, which contains different factors and chemical substances. Thus, herein, we explored the role and underlying mechanism of H-EXOs on cerebral inflammation in I/R injured rats.</p>
<p>The increased levels of IL-1&#x3b2;, TNF-&#x3b1; and IL-6 and the phosphorylation of P65 are the key phenomena that reflect the degree of injury caused by an inflammatory response (<xref ref-type="bibr" rid="B25">Li et al., 2014</xref>; <xref ref-type="bibr" rid="B50">Wang et al., 2020</xref>). Ischemic stroke results in an increase in the secretion of inflammatory factors, which activates the NF-&#x3ba;B pathway and promotes P65 phosphorylation, thereby further stimulating the production of inflammatory factors (<xref ref-type="bibr" rid="B21">Kong et al., 2022</xref>; <xref ref-type="bibr" rid="B32">Luo et al., 2022</xref>). In our study, the levels of IL-1&#x3b2;, TNF-&#x3b1; and IL-6, and the phosphorylation of P65 were significantly increased in the rat brain tissue and cultured HT22 cells after ischemia-reperfusion injury (<xref ref-type="fig" rid="F2">Figures 2F&#x2013;H</xref>; <xref ref-type="fig" rid="F3">Figures 3B&#x2013;D</xref>), which is consistent with other researchers&#x2019; findings (<xref ref-type="bibr" rid="B1">Althurwi et al., 2022</xref>). H-EXOs significantly inhibited the upregulation of these inflammatory factors&#x2019; expression. Previous studies have demonstrated that neurons, especially in the CA1 area of the hippocampus, are particularly sensitive to ischemic damage. Nissl staining was performed to assess the morphological changes present in the injured areas of the rat brain. Our result indicated that most neurons from the H-EXO-treated rats showed a relatively intact morphology, with only a few cells displaying nuclear condensation and reduced Nissl bodies, compared with those from the rats without H-EXO-treatment (<xref ref-type="fig" rid="F2">Figure 2D</xref>). Collectively, we confirmed that H-EXOs could protect neurons from ischemia-reperfusion injury through the suppression of the inflammatory response.</p>
<p>We wondered the underlying mechanism of the anti-inflammatory action of H-EXOs involved in I/R injury. Extensive evidence suggests that the role of exosomes in ischemic stroke may be associated with the function as messengers in intercellular communication. During the treatment process for cerebral ischemia, exosomes secrete a variety of factors and modulate the expression of endogenous target genes (<xref ref-type="bibr" rid="B7">Cheng et al., 2021</xref>; <xref ref-type="bibr" rid="B13">Guo et al., 2021</xref>; <xref ref-type="bibr" rid="B16">Huang et al., 2021</xref>). Therefore, we wanted to know the factors that are involved in the anti-inflammatory effect of H-EXOs. We have previously shown that transcription factor KLF14 expression is upregulated in primary neurons after OGD45min/R6h injury (<xref ref-type="bibr" rid="B42">Shi et al., 2017</xref>). KLF14, as one of the KLF family members, which is widely expressed in many tissues and involved in the regulation of many cellular processes, including embryogenesis, proliferation, differentiation, apoptosis, etc. (<xref ref-type="bibr" rid="B4">Chen et al., 2020</xref>). KLF14 has a role in immune regulation, but has different regulatory functions in different disease states (<xref ref-type="bibr" rid="B54">Xie et al., 2017</xref>; <xref ref-type="bibr" rid="B9">Du et al., 2021</xref>), and the reduction of KLF14 expression was found to increase the expression of inflammatory factors TNF-&#x3b1;, IL-1&#x3b2;, and IL-6. This effect could be reversed by KLF14 overexpression (<xref ref-type="bibr" rid="B15">Hu et al., 2018</xref>; <xref ref-type="bibr" rid="B5">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="B59">Yuan et al., 2022</xref>). Based on the above, we wonder whether the anti-inflammatory effects of H-EXOs are related to KLF14. In the present study, we observed an increase in the expression of KLF14 in the rat brain tissue and HT22 cells after I/R injury (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;F</xref>). The role of KLF14 in cerebral ischemic injury has not yet been studied. To fill the blank, we overexpressed and downregulated the expression levels of KLF14 in OGD/R treated HT22 cells.The results indicated that KLF14 overexpression improved cell viability and suppressed the inflammatory response of HT22 cells after OGD/R (<xref ref-type="fig" rid="F4">Figure 4J&#x2013;M</xref>). Meanwhile KLF14 downregulation by using siRNA led to a reduction in cell viability and an elevated inflammatory response (<xref ref-type="fig" rid="F4">Figure 4Q&#x2013;T</xref>). Taken together, KLF14 is involved in the pathological process of brain I/R injury and exerts protective effects by inhibiting the production of pro-inflammatory factors. This finding underscores the pathological mechanism of ischemic stroke and provides a new therapeutic strategy.</p>
<p>In this study, the treatment with H-EXOs after I/R injury further increased the expression of KLF14 (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;F</xref>). Neurons are susceptible to damage after ischemic stroke, and it is of great importance to study them, so in the present study we examined the changes in KLF14 expression in neuronal cells after ischemia-reperfusion injury. Whether there are changes in KLF14 expression in other types of cells needs to be explored in more experiments. The increased KLF14 in H-EXOs treated cells may come from the exosomes or from their induction. To give an explicit answer, we tested the protein level of KLF14 in H-EXOs but could not observe any strong signal (<xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>), which may suggest that H-EXOs induced the expression of KLF14 in neuronal cells after I/R injury, and whether there is more KLF14 protein expression in the exosomes secreted by ischemia preconditioned HUVEC needs to be further investigated. Besides, siKLF14 reversed the anti-inflammatory effect of H-EXOs (<xref ref-type="fig" rid="F5">Figures 5D&#x2013;G</xref>). Overall, H-EXOs exerted anti-inflammatory effects in neurons after ischemic stroke via upregulating the expression of KLF14.</p>
<p>In the present study, we investigated that H-EXOs could partially inhibit the inflammatory responses after I/R injury. The pathophysiology of brain ischemia-reperfusion injury is terribly complicated, involving various mechanisms, including excitotoxicity, oxidative stress, neuroinflammation, and apoptosis (<xref ref-type="bibr" rid="B41">Qin et al., 2022</xref>). It is known that KLF14 overexpression suppresses inflammatory effects by inhibiting P65 transcription (<xref ref-type="bibr" rid="B28">Liu et al., 2022</xref>). However, H-EXOs treatment did not change the expression of P65 but inhibited the phosphorylation of P65 in our study. Maybe H-EXOs regulate P65 expression with other mechanisms. Recent studies suggested that the expression of KLF14 can be influenced by the activated transforming growth factor &#x3b2; (TGF-&#x3b2;) pathway (<xref ref-type="bibr" rid="B12">Gonzalez et al., 2013</xref>; <xref ref-type="bibr" rid="B3">Chen L. et al., 2023</xref>) or microRNAs, and it also can regulate other miRNAs (<xref ref-type="bibr" rid="B26">Li et al., 2020</xref>; <xref ref-type="bibr" rid="B6">Chen X. Z. et al., 2023</xref>). It is very likely that the miRNAs from H-EXOs regulate KLF14 expression, and this hypothesis will be confirmed by our further study. We will also elucidate whether H-EXOs exert other important effects at different stages of the pathological processes of ischemic stroke. Although exosomes have been proposed as a therapeutic approach and potential biomarkers for stroke (<xref ref-type="bibr" rid="B34">Otero-Ortega et al., 2019</xref>; <xref ref-type="bibr" rid="B17">Jafarzadeh-Esfehani et al., 2020</xref>; <xref ref-type="bibr" rid="B57">Yang et al., 2021</xref>), the clinical application is still limited. Thus, it is important to validate the effects of H-EXOs treatment in other animal models of brain ischemic stroke to promote its clinical application.</p>
<p>In conclusion, our research suggests that KLF14 might be a potential target for the treatment of cerebral ischemic injury, and H-EXOs are promising to be a therapeutic strategy for ischemic stroke.</p>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Materials</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s6">
<title>Ethics statement</title>
<p>The animal studies were approved by Model Animal Research Center of Nantong University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the owners for the participation of their animals in this study.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>JQ: Writing&#x2013;original draft. LZ: Writing&#x2013;original draft. LY: Writing&#x2013;original draft. JY: Writing&#x2013;original draft. FW: Writing&#x2013;original draft. JZ: Writing&#x2013;original draft. YG: Writing&#x2013;original draft. GC: Writing&#x2013;review and editing. XC: Writing&#x2013;original draft, Writing&#x2013;review and editing.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by Postgraduate Research &#x26; Practice Innovation Program of Jiangsu Province (No. KYCX23_3418) and Nantong Grant from the Key special science and technology plan projects of COVID-19 for People&#x2019;s livelihood (No. H202136).</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>Authors FW and JZ were employed by Nantong Xingzhong Cell Engineering Co. Ltd.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2024.1365928/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2024.1365928/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.DOCX" id="SM1" mimetype="application/DOCX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image1.JPEG" id="SM2" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image2.JPEG" id="SM3" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table2.DOCX" id="SM4" mimetype="application/DOCX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Althurwi</surname>
<given-names>H. N.</given-names>
</name>
<name>
<surname>Abdel-Rahman</surname>
<given-names>R. F.</given-names>
</name>
<name>
<surname>Soliman</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Ogaly</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Alkholifi</surname>
<given-names>F. K.</given-names>
</name>
<name>
<surname>Abd-Elsalam</surname>
<given-names>R. M.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Protective effect of beta-carotene against myeloperoxidase- mediated oxidative stress and inflammation in rat ischemic brain injury</article-title>. <source>Antioxidants (Basel)</source> <volume>11</volume> (<issue>12</issue>), <fpage>2344</fpage>. <pub-id pub-id-type="doi">10.3390/antiox11122344</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baranovicova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kalenska</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tomascova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Holubcikova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lehotsky</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Time-related metabolomics study in the rat plasma after global cerebral ischemia and reperfusion: effect of ischemic preconditioning</article-title>. <source>IUBMB Life</source> <volume>72</volume> (<issue>9</issue>), <fpage>2010</fpage>&#x2013;<lpage>2023</lpage>. <pub-id pub-id-type="doi">10.1002/iub.2340</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sha</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F. T.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C. L.</given-names>
</name>
<etal/>
</person-group> (<year>2023a</year>). <article-title>Upregulation of KLF14 expression attenuates kidney fibrosis by inducing PPAR&#x3b1;-mediated fatty acid oxidation</article-title>. <source>Free Radic. Biol. Med.</source> <volume>195</volume>, <fpage>132</fpage>&#x2013;<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2022.12.096</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The role of KLF14 in multiple disease processes</article-title>. <source>Biofactors</source> <volume>46</volume> (<issue>2</issue>), <fpage>276</fpage>&#x2013;<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1002/biof.1612</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Overexpression of KLF14 protects against immune-mediated hepatic injury in mice</article-title>. <source>Lab. Invest.</source> <volume>99</volume> (<issue>1</issue>), <fpage>37</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1038/s41374-018-0134-4</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X. Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W. X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>R. G.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>J. X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q. J.</given-names>
</name>
<etal/>
</person-group> (<year>2023b</year>). <article-title>KLF14/miR-1283/TFAP2C axis inhibits HER2-positive breast cancer progression via declining tumor cell proliferation</article-title>. <source>Mol. Carcinog.</source> <volume>62</volume> (<issue>4</issue>), <fpage>532</fpage>&#x2013;<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1002/mc.23505</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>MSCs-derived exosomes attenuate ischemia-reperfusion brain injury and inhibit microglia apoptosis might via exosomal miR-26a-5p mediated suppression of CDK6</article-title>. <source>Mol. Med.</source> <volume>27</volume> (<issue>1</issue>), <fpage>67</fpage>. <pub-id pub-id-type="doi">10.1186/s10020-021-00324-0</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Astrocytes-derived exosomes pre-treated by berberine inhibit neuroinflammation after stroke via miR-182-5p/Rac1 pathway</article-title>. <source>Int. Immunopharmacol.</source> <volume>118</volume>, <fpage>110047</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2023.110047</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>EZH2-mediated inhibition of KLF14 expression promotes HSCs activation and liver fibrosis by downregulating PPAR&#x3b3;</article-title>. <source>Cell Prolif.</source> <volume>54</volume> (<issue>7</issue>), <fpage>e13072</fpage>. <pub-id pub-id-type="doi">10.1111/cpr.13072</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferguson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Deci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The phenotypic effects of exosomes secreted from distinct cellular sources: a comparative study based on miRNA composition</article-title>. <source>Aaps J.</source> <volume>20</volume> (<issue>4</issue>), <fpage>67</fpage>. <pub-id pub-id-type="doi">10.1208/s12248-018-0227-4</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Brozopine inhibits 15-LOX-2 metabolism pathway after transient focal cerebral ischemia in rats and OGD/R-Induced hypoxia injury in PC12 cells</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>99</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00099</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Vallcaneras</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Calandra</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Gonzalez Calvar</surname>
<given-names>S. I.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Involvement of KLF14 and egr-1 in the TGF-beta1 action on Leydig cell proliferation</article-title>. <source>Cytokine</source> <volume>61</volume> (<issue>2</issue>), <fpage>670</fpage>&#x2013;<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2012.12.009</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Surface-modified engineered exosomes attenuated cerebral ischemia/reperfusion injury by targeting the delivery of quercetin towards impaired neurons</article-title>. <source>J. Nanobiotechnology</source> <volume>19</volume> (<issue>1</issue>), <fpage>141</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-021-00879-4</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Exosome theranostics: biology and translational medicine</article-title>. <source>Theranostics</source> <volume>8</volume> (<issue>1</issue>), <fpage>237</fpage>&#x2013;<lpage>255</lpage>. <pub-id pub-id-type="doi">10.7150/thno.21945</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Kr&#xfc;ppel-like factor 14, a coronary artery disease associated transcription factor, inhibits endothelial inflammation via NF-&#x3ba;B signaling pathway</article-title>. <source>Atherosclerosis</source> <volume>278</volume>, <fpage>39</fpage>&#x2013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2018.09.018</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Baicalin-loaded macrophage-derived exosomes ameliorate ischemic brain injury via the antioxidative pathway</article-title>. <source>Mater Sci. Eng. C Mater Biol. Appl.</source> <volume>126</volume>, <fpage>112123</fpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2021.112123</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jafarzadeh-Esfehani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Soudyab</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Parizadeh</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Jaripoor</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Nejad</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Shariati</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Circulating exosomes and their role in stroke</article-title>. <source>Curr. Drug Targets</source> <volume>21</volume> (<issue>1</issue>), <fpage>89</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.2174/1389450120666190821153557</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Justin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Divakar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ramanathan</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Cerebral ischemia induced inflammatory response and altered glutaminergic function mediated through brain AT(1) and not AT(2) receptor</article-title>. <source>Biomed. Pharmacother.</source> <volume>102</volume>, <fpage>947</fpage>&#x2013;<lpage>958</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.03.164</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalluri</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>LeBleu</surname>
<given-names>V. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The biology, function, and biomedical applications of exosomes</article-title>. <source>Science</source> <volume>367</volume> (<issue>6478</issue>), <fpage>eaau6977</fpage>. <pub-id pub-id-type="doi">10.1126/science.aau6977</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Coveney</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Purroy</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lemmens</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tsivgoulis</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Anti-inflammatory approaches to ischaemic stroke prevention</article-title>. <source>J. Neurology, Neurosurg. Psychiatry</source> <volume>89</volume> (<issue>2</issue>), <fpage>211</fpage>&#x2013;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp-2016-314817</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>mtDNA-STING Axis mediates microglial polarization via IRF3/NF-&#x3ba;B signaling after ischemic stroke</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <fpage>860977</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.860977</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kunz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dirnagl</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Mergenthaler</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Acute pathophysiological processes after ischaemic and traumatic brain injury</article-title>. <source>Best Pract. Res. Clin. Anaesthesiol.</source> <volume>24</volume> (<issue>4</issue>), <fpage>495</fpage>&#x2013;<lpage>509</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpa.2010.10.001</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Melatonin regulates microglial polarization and protects against ischemic stroke-induced brain injury in mice</article-title>. <source>Exp. Neurol.</source> <volume>367</volume>, <fpage>114464</fpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2023.114464</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Eljaafari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bensoussan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Latger-Cannard</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Serrurier</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Human umbilical vein endothelial cells increase <italic>ex vivo</italic> expansion of human CD34(&#x002B;) PBPC through IL-6 secretion</article-title>. <source>Cytotherapy</source> <volume>8</volume> (<issue>4</issue>), <fpage>335</fpage>&#x2013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1080/14653240600845062</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y. W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H. T.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Protective effect of tea polyphenols on renal ischemia/reperfusion injury via suppressing the activation of TLR4/NF-&#x3ba;B p65 signal pathway</article-title>. <source>Gene</source> <volume>542</volume> (<issue>1</issue>), <fpage>46</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2014.03.021</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>CircTADA2A suppresses the progression of colorectal cancer via miR-374a-3p/KLF14 axis</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>39</volume> (<issue>1</issue>), <fpage>160</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-020-01642-7</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H. D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G. Z.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Exosomes from bone marrow mesenchymal stem cells are a potential treatment for ischemic stroke</article-title>. <source>Neural Regen. Res.</source> <volume>18</volume> (<issue>10</issue>), <fpage>2246</fpage>&#x2013;<lpage>2251</lpage>. <pub-id pub-id-type="doi">10.4103/1673-5374.369114</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The transcription factor KLF14 attenuates LPS-induced acute lung injury by ameliorating apoptosis of alveolar epithelial cells in mice</article-title>. <source>Mol. Immunol.</source> <volume>152</volume>, <fpage>67</fpage>&#x2013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2022.10.002</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Bone marrow mesenchymal stem cell-derived exosomes attenuate cerebral ischemia-reperfusion injury-induced neuroinflammation and pyroptosis by modulating microglia M1/M2 phenotypes</article-title>. <source>Exp. Neurol.</source> <volume>341</volume>, <fpage>113700</fpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2021.113700</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longa</surname>
<given-names>E. Z.</given-names>
</name>
<name>
<surname>Weinstein</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cummins</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>Reversible middle cerebral artery occlusion without craniectomy in rats</article-title>. <source>Stroke</source> <volume>20</volume> (<issue>1</issue>), <fpage>84</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1161/01.str.20.1.84</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>L&#xf6;tvall</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Hochberg</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Buz&#xe1;s</surname>
<given-names>E. I.</given-names>
</name>
<name>
<surname>Di Vizio</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gardiner</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles</article-title>. <source>J. Extracell. Vesicles</source> <volume>3</volume>, <fpage>26913</fpage>. <pub-id pub-id-type="doi">10.3402/jev.v3.26913</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Intermittent theta-burst stimulation improves motor function by inhibiting neuronal pyroptosis and regulating microglial polarization via TLR4/NF&#x3ba;B/NLRP3 signaling pathway in cerebral ischemic mice</article-title>. <source>J. Neuroinflammation</source> <volume>19</volume> (<issue>1</issue>), <fpage>141</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-022-02501-2</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahemuti</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kadeer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Abula</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aili</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Maimaiti</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>TSPO exacerbates acute cerebral ischemia/reperfusion injury by inducing autophagy dysfunction</article-title>. <source>Exp. Neurol.</source> <volume>369</volume>, <fpage>114542</fpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2023.114542</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otero-Ortega</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Laso-Garc&#xed;a</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>G&#xf3;mez-de Frutos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fuentes</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Diekhorst</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>D&#xed;ez-Tejedor</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Role of exosomes as a treatment and potential biomarker for stroke</article-title>. <source>Transl. Stroke Res.</source> <volume>10</volume> (<issue>3</issue>), <fpage>241</fpage>&#x2013;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1007/s12975-018-0654-7</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>MiR-17-5p mediates the effects of ACE2-enriched endothelial progenitor cell-derived exosomes on ameliorating cerebral ischemic injury in aged mice</article-title>. <source>Mol. Neurobiol.</source> <volume>60</volume> (<issue>6</issue>), <fpage>3534</fpage>&#x2013;<lpage>3552</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-023-03280-4</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parvez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kaushik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tabassum</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Dodging blood brain barrier with &#x201c;nano&#x201d; warriors: novel strategy against ischemic stroke</article-title>. <source>Theranostics</source> <volume>12</volume> (<issue>2</issue>), <fpage>689</fpage>&#x2013;<lpage>719</lpage>. <pub-id pub-id-type="doi">10.7150/thno.64806</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pascual</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Do Couto</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Alfonso-Loeches</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aguilar</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Rodriguez-Arias</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guerri</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Changes in histone acetylation in the prefrontal cortex of ethanol-exposed adolescent rats are associated with ethanol-induced place conditioning</article-title>. <source>Neuropharmacology</source> <volume>62</volume> (<issue>7</issue>), <fpage>2309</fpage>&#x2013;<lpage>2319</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.01.011</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>D. D.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>E. J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Exosomes in atherosclerosis, a double-edged sword: their role in disease pathogenesis and their potential as novel therapeutics</article-title>. <source>Aaps J.</source> <volume>23</volume> (<issue>5</issue>), <fpage>95</fpage>. <pub-id pub-id-type="doi">10.1208/s12248-021-00621-w</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Exosomal ZEB1 derived from neural stem cells reduces inflammation injury in OGD/R-Treated microglia via the GPR30-TLR4-NF-&#x3ba;b Axis</article-title>. <source>Neurochem. Res.</source> <volume>48</volume> (<issue>6</issue>), <fpage>1811</fpage>&#x2013;<lpage>1821</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-023-03866-3</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prabhakaran</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ruff</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Acute stroke intervention: a systematic review</article-title>. <source>Jama</source> <volume>313</volume> (<issue>14</issue>), <fpage>1451</fpage>&#x2013;<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2015.3058</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>X. W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Correction To: signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions</article-title>. <source>Signal Transduct. Target Ther.</source> <volume>7</volume> (<issue>1</issue>), <fpage>278</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-022-01129-1</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Neuron-autonomous transcriptome changes upon ischemia/reperfusion injury</article-title>. <source>Sci. Rep.</source> <volume>7</volume> (<issue>1</issue>), <fpage>5800</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-05342-9</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>tPA mobilizes immune cells that exacerbate hemorrhagic transformation in stroke</article-title>. <source>Circulation Res.</source> <volume>128</volume> (<issue>1</issue>), <fpage>62</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.317596</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simons</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Raposo</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Exosomes--vesicular carriers for intercellular communication</article-title>. <source>Curr. Opin. Cell Biol.</source> <volume>21</volume> (<issue>4</issue>), <fpage>575</fpage>&#x2013;<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1016/j.ceb.2009.03.007</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>T. G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Role of nuclear factor kappa B (NF-&#x3ba;B) signalling in neurodegenerative diseases: an mechanistic approach</article-title>. <source>Curr. Neuropharmacol.</source> <volume>18</volume> (<issue>10</issue>), <fpage>918</fpage>&#x2013;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.2174/1570159X18666200207120949</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Electroacupuncture ameliorates neuronal injury by NLRP3/ASC/Caspase-1 mediated pyroptosis in cerebral ischemia-reperfusion</article-title>. <source>Mol. Neurobiol.</source> <volume>61</volume> (<issue>4</issue>), <fpage>2357</fpage>&#x2013;<lpage>2366</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-023-03712-1</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Niel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>D&#x2019;Angelo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Raposo</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Shedding light on the cell biology of extracellular vesicles</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>19</volume> (<issue>4</issue>), <fpage>213</fpage>&#x2013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1038/nrm.2017.125</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verweij</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Revenu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Arras</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dingli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Loew</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pegtel</surname>
<given-names>D. M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Live tracking of inter-organ communication by endogenous exosomes <italic>in vivo</italic>
</article-title>. <source>Dev. Cell</source> <volume>48</volume> (<issue>4</issue>), <fpage>573</fpage>&#x2013;<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2019.01.004</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ping</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases</article-title>. <source>Sci. Adv.</source> <volume>8</volume> (<issue>37</issue>), <fpage>eabp9435</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abp9435</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ru</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Melatonin enhances the therapeutic effect of plasma exosomes against cerebral ischemia-induced pyroptosis through the TLR4/NF-&#x3ba;B pathway</article-title>. <source>Front. Neurosci.</source> <volume>14</volume>, <fpage>848</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2020.00848</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X. T.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>D. C.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Selenocysteine antagonizes oxygen glucose deprivation-induced damage to hippocampal neurons</article-title>. <source>Neural Regen. Res.</source> <volume>13</volume> (<issue>8</issue>), <fpage>1433</fpage>&#x2013;<lpage>1439</lpage>. <pub-id pub-id-type="doi">10.4103/1673-5374.235300</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Crack</surname>
<given-names>P. J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Modulation of neuro-inflammation and vascular response by oxidative stress following cerebral ischemia-reperfusion injury</article-title>. <source>Curr. Med. Chem.</source> <volume>15</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.2174/092986708783330665</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis</article-title>. <source>Drug Deliv.</source> <volume>29</volume> (<issue>1</issue>), <fpage>1257</fpage>&#x2013;<lpage>1271</lpage>. <pub-id pub-id-type="doi">10.1080/10717544.2022.2057617</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>W. D.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>C. K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The role of Kr&#xfc;ppel-like factor 14 in the pathogenesis of atherosclerosis</article-title>. <source>Atherosclerosis</source> <volume>263</volume>, <fpage>352</fpage>&#x2013;<lpage>360</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2017.06.011</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamaguchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tashiro</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Yoshidomi</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>1996</year>). <article-title>Umbilical vein endothelial cells are an important source of c-kit and stem cell factor which regulate the proliferation of haemopoietic progenitor cells</article-title>. <source>Br. J. Haematol.</source> <volume>94</volume> (<issue>4</issue>), <fpage>606</fpage>&#x2013;<lpage>611</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2141.1996.d01-1855.x</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamaguchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tashiro</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Miyazaki</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Role of umbilical vein endothelial cells in hematopoiesis</article-title>. <source>Leuk. Lymphoma</source> <volume>31</volume> (<issue>1-2</issue>), <fpage>61</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.3109/10428199809057585</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Challenges and improvements of novel therapies for ischemic stroke</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>721156</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.721156</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yildirim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Boehmler</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Kanz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>M&#xf6;hle</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Expansion of cord blood CD34&#x002B; hematopoietic progenitor cells in coculture with autologous umbilical vein endothelial cells (HUVEC) is superior to cytokine-supplemented liquid culture</article-title>. <source>Bone Marrow Transpl.</source> <volume>36</volume> (<issue>1</issue>), <fpage>71</fpage>&#x2013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bmt.1705001</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>The transcription factor KLF14 regulates macrophage glycolysis and immune function by inhibiting HK2 in sepsis</article-title>. <source>Cell Mol. Immunol.</source> <volume>19</volume> (<issue>4</issue>), <fpage>504</fpage>&#x2013;<lpage>515</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-021-00806-5</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaulyanov</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Simpkins</surname>
<given-names>J. W.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Glutamate receptor requirement for neuronal death from anoxia-reoxygenation: an <italic>in vitro</italic> model for assessment of the neuroprotective effects of estrogens</article-title>. <source>Cell Mol. Neurobiol.</source> <volume>19</volume> (<issue>6</issue>), <fpage>705</fpage>&#x2013;<lpage>718</lpage>. <pub-id pub-id-type="doi">10.1023/a:1006948921855</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Inflammation and tumor progression: signaling pathways and targeted intervention</article-title>. <source>Signal Transduct. Target Ther.</source> <volume>6</volume> (<issue>1</issue>), <fpage>263</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-021-00658-5</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>